NCT06700408Not yet recruitingPhase 2
RCT for the Chinese Medicine in Treating Hypercholesterolemia
Efficacy and Safety of Dachaihu Decoction Combined Erzhiwan With Variation for the Treatment of Hypercholesterolemia: A Parallel, Randomized, Double-blinded, Placebo-controlled Trial
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 20 Nov 2024
- Start date
- Jan 2027
- Primary completion date
- Dec 2029
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT06700408
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 70
- From Jan 2027 to the primary completion date, Dec 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking drugs that may affect lipid metabolism (such as steroids, sleeping pills, and psychotropic drugs);
- Alcohol or drug abuse within the last 3 months;
- Participate in other interventional clinical trials within 3 months before the study, including drugs, supplements, medical devices, etc.;
Other illness
- History of severe cardiovascular and cerebrovascular diseases; or history of psychiatric illness;
- Known pregnant or lactating women, allergies or allergies to traditional Chinese medicine;
Other
- Known liver function or renal dysfunction;
- Patients with known secondary hypercholesterolemia.
Who the study is looking for
- Age 18-80 years old, any gender;
- LDL-C level of 4.1 mmol/L or above (no statin therapy during the screening period);
- Be able to maintain a more consistent lifestyle and eating habits throughout the study;
- Have a fixed residence and are not expected to move or travel for 8 weeks;
- Voluntarily sign the informed consent form.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.